<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752919</url>
  </required_header>
  <id_info>
    <org_study_id>16214</org_study_id>
    <secondary_id>H9H-MC-JBEI</secondary_id>
    <secondary_id>2015-005261-23</secondary_id>
    <nct_id>NCT02752919</nct_id>
  </id_info>
  <brief_title>Study of Galunisertib in Healthy Participants</brief_title>
  <official_title>A Single Dose Study to Evaluate the Exposure-Response Relationship Between Galunisertib (LY2157299) and QT Interval in Healthy Japanese and Non-Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study involves a single dose of galunisertib taken by mouth by Japanese participants and&#xD;
      non-Japanese participants. The study will evaluate the relationship between the effect of the&#xD;
      study drug on the electrical activity of the heart, as measured by electrocardiogram (ECG)&#xD;
      and how much of the study drug gets into the blood stream and how long it takes the body to&#xD;
      remove it. Ths study will last about 42 days for each participant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Change from Baseline in Fridericia-corrected QT Interval (QTcF) by Specific Galunisertib Concentrations</measure>
    <time_frame>Baseline through 72 hours after administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Drug Concentration (Cmax) of Galunisertib</measure>
    <time_frame>Predose through 72 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of Cmax (tmax) of Galunisertib</measure>
    <time_frame>Predose through 72 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Galunisertib</measure>
    <time_frame>Predose through 72 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A Galunisertib - 1 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of galunisertib in Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Galunisertib - 2 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of galunisertib in Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Galunisertib - 1 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of galunisertib in non-Japanese participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Galunisertib - 2 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of galunisertib in non-Japanese participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galunisertib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A Galunisertib - 1 tablet</arm_group_label>
    <arm_group_label>Part A Galunisertib - 2 tablets</arm_group_label>
    <arm_group_label>Part B Galunisertib - 1 tablet</arm_group_label>
    <arm_group_label>Part B Galunisertib - 2 tablets</arm_group_label>
    <other_name>LY2157299</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy male or female Japanese or non-Japanese participants, as&#xD;
             determined by medical history and physical examination.&#xD;
&#xD;
          -  Male participants: Must agree to use a reliable method of birth control for 12 weeks&#xD;
             after receiving the dose of study drug, OR be at least 6 weeks post-vasectomy with&#xD;
             documentation of sperm-free ejaculate.&#xD;
&#xD;
          -  Female participants: Women not of child-bearing potential may participate, and include&#xD;
             those who are:&#xD;
&#xD;
               -  Infertile due to surgical sterilization; or&#xD;
&#xD;
               -  Postmenopausal.&#xD;
&#xD;
          -  All female participants must test negative for pregnancy at screening.&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/mÂ²),&#xD;
             inclusive at screening.&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range.&#xD;
&#xD;
          -  Are able and willing to give signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have participated, within the last 3 months, in a clinical trial involving an&#xD;
             Investigational Product (IP). If the previous IP has a long half-life, 3 months should&#xD;
             have passed.&#xD;
&#xD;
          -  Have known allergies to galunisertib-related compounds or any components of the&#xD;
             formulation, or history of significant atopy.&#xD;
&#xD;
          -  Have a personal or family history of long QT syndrome, heart failure, hypokalemia, or&#xD;
             sudden death.&#xD;
&#xD;
          -  Have a personal history of unexplained syncope within the last year.&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the&#xD;
             investigator, increases the risks associated with participating in the study or&#xD;
             affects or confounds the corrected QT (QTc) analysis (the ECG waveform morphology or&#xD;
             rhythm are incompatible with reliable measurement of ECG intervals), or have QTcF&#xD;
             greater than (&gt;) 450 milliseconds (msec).&#xD;
&#xD;
          -  Have an abnormal blood pressure as determined by the investigator.&#xD;
&#xD;
          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs; of&#xD;
             constituting a risk when taking the IP; or of interfering with the interpretation of&#xD;
             data.&#xD;
&#xD;
          -  Have serum magnesium and potassium values outside of the normal reference range.&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) infection, hepatitis C or&#xD;
             hepatitis B.&#xD;
&#xD;
          -  Intend to use over-the-counter or prescription medication (including herbal&#xD;
             medications) within 14 days prior to dosing.&#xD;
&#xD;
          -  Have donated blood of more than 500 milliliter (mL) within the last month&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14&#xD;
             units per week (females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

